A novel metered dose transdermal spray formulation for oxybutynin

Indian Journal of Pharmaceutical Sciences

Volumn 70, Issue 6, 2008, Pages 733-739

  Bakshi, A ^a   Bajaj, A ^a   Malhotra, G ^a   Madan, M ^a   Amrutiya, N ^a  

^a SNDT WOMEN S UNIVERSITY   (India)

Author keywords

In vitro release; Kinetics; Oxybutynin; Transdermal spray

Indexed keywords

155 A GPC; 165 AGPC; 25140 BGP; 8PH 11038; 8PH 11633; ACETONE; ALCOHOL; CARBOMER; CB 18131; METHANOL; OXYBUTYNIN; POLOXAMER; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIFFUSION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SCREENING; EVAPORATION; FEMALE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PH; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SKIN IRRITATION;

EID: 64349094582     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.49094     Document Type: Article

References (16)

1. Chong S, Fung HL. Transdermal drug delivery systems: Pharmacokinetics, clinical efficacy, and tolerance development. In: Hadgraft J, Guy RH, editors. Transdermal Drug Delivery: Developmental Issues and Research Initiatives. New York: Marcel Dekker; 1989. p.135.
2. Lin S, Chien YW. Transdermal contraceptive patches: Development, clinical performance, and future prospects. Am J Drug Delivery 2006;4:201-13.
3. Ji-Hui Z, Ji-Hua F, Shu-Ming W, Chang-Hai S, Ying S, Shu-Jia K et al. A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: In vitro and in vivo characterization. Int J Pharm 2007;337:88-101.
4. Ranade VV. Drug delivery systems: Transdermal drug delivery. J Clin Pharmacol 1991;31:401-18.
5. Modamio P, Lastra CF, Marino EL. A comparative in vitro study of percutaneous penetration of beta-blockers in human skin. Int J Pharm 2000;194:249-59.
6. Ke GM, Wang L, Xue HY, Lu WL, Zhang X, Zhang Q, et al. In vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children. Biol Pharm Bull 2005;28:305-10.
7. Schaison G, Couzinet B, Behre HM. Percutaneous dihydrotestosterone treatment. In: Nieschlag E, editor. Testosteroneaction, deficiency, substitution, 2nd ed. Berlin: Springer-Verlag; 1998. p. 329-48.
8. Marie-Laure L, Herve R, Patrick W, Richard HG. Formulation and evaluation of testosterone transdermal spray. J Pharm Sci 2006;95:1693-702.
9. Morgan TM. Metered dose transdermal spray (MDTS). In: Hagraft J, editor. Modified release drug delivery technology, New York, NY: Marcel Dekker; 2003. p. 523-31.
10. Wein AJ, Rackley RR. Overactive bladder: A better understanding of pathophysiology, diagnosis and management. J Urol 2006;175:S5-10.
11. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53.
12. Andersson KE, Chapple CR. Oxybutynin and the overactive bladder. World J Urol 2001;19:319-23.
13. Dmochowski RR, Nitti V, Staskin D, Luber K, Appell R, Davila GW. Transdermal oxybutynin in the treatment of adults with overactive bladder: Combined results of two randomized clinical trials. World J Urol 2005;23:263-70.
14. Howard RZ, Bernhard S, Alexander F, Danyi Q, Steven WS. Pharmacokinetics of the R- and S- enantiomers of Oxybutynin and N-desethyl oxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 2001;18:1029-34.
15. Ron ES, Tamarkin D. Ophthalmic and mucosal preparations. United States Patent 2001. 6204270.
16. Lee ES, Watanabe TG, Robert M, Burkoth TL. Monoglyceride/ lactate ester permeation enhancer for oxybutnin. United States Patent 1999, 5900250.